US4808610A - Mometasone furoate anti-inflammatory cream composition using hexylene glycol - Google Patents
Mometasone furoate anti-inflammatory cream composition using hexylene glycol Download PDFInfo
- Publication number
- US4808610A US4808610A US06/914,227 US91422786A US4808610A US 4808610 A US4808610 A US 4808610A US 91422786 A US91422786 A US 91422786A US 4808610 A US4808610 A US 4808610A
- Authority
- US
- United States
- Prior art keywords
- percent
- water
- pharmaceutical composition
- mometasone furoate
- topical pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960002744 mometasone furoate Drugs 0.000 title claims abstract description 15
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title claims abstract description 15
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 title claims description 30
- 229940051250 hexylene glycol Drugs 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title abstract description 29
- 239000006071 cream Substances 0.000 title abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 13
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 claims description 10
- 235000019271 petrolatum Nutrition 0.000 claims description 10
- 239000004408 titanium dioxide Substances 0.000 claims description 10
- 239000003871 white petrolatum Substances 0.000 claims description 10
- 229940045860 white wax Drugs 0.000 claims description 9
- 229940073669 ceteareth 20 Drugs 0.000 claims description 8
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 claims description 2
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229940100608 glycol distearate Drugs 0.000 claims description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 19
- 230000000699 topical effect Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 whiteners Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- U.S. Pat. No. 4,472,393 discloses 3,20-dioxo-1,4-pregnadiene-17 ⁇ -ol-17-aromatic heterocycle carboxylate compounds, pharmaceutical compositions containing said compounds and methods for the treatment and control of inflammatory conditions with said compounds. Included in the compounds disclosed in this patent is mometasone furoate which is insoluble in water and has poor solubility in solvents frequently utilized in topical preparations. Such poor solubility characteristics hindered the development of a cosmetically elegant cream with superior anti-inflammatory activity.
- the formulation of the present invention provides a cream formulation having cosmetic elegance and outstanding efficacy.
- the formulation is of value in the topical treatment of dermatological disorders such as contact and allergic dermatitis, eczemas and psoriasis. Treatment with the formulation of this invention is usually accomplished by applying it to completely cover the affected area. The usual frequency of application is once daily, although adequate maintenance therapy for some patients may be achieved with less frequent application.
- the formulation of the present invention is a unique drug co-solvent-in-oil emulsion for administration to warm-blooded animals, including man, containing as the active anti-inflammatory ingredient an effective amount of mometasone furoate.
- the internal phase of the emulsion is the drug co-solvent component comprising the hexylene glycol water mixture.
- pharmaceutically acceptable adjuvants, stabilizers, preservatives, whiteners, buffers and surfactants are used in the formulation of this invention.
- the formulation of the present invention comprises:
- Sufficient acid is added to adjust the pH of the purified water to pH 2.5 ⁇ 0.2; charged as a 10% w/v solution.
- acids which can be utilized in the cream formulation are phosphoric acid, hydrochloric acid, acetic acid, and the like.
- the preferred acid is phosphoric acid.
- the formulation comprises:
- This formulation results in an elegant stable, water-washable cream with excellent anti-inflammatory activity.
- This cream is also self-preserving.
- the HLB is defined by Griffin, W. C., J. Soc. Cosmetic Chemist, 1,311 [1949] and 5,249 [1949].
- the HLB reflects the balance between hydrophilic and lipophilic strength of the emulsifiers. The higher HLB, indicates a stronger hydrophilic tendency of the emulsification system.
- the formulations of the present invention are manufactured in a conventional manner by thoroughly mixing the ingredients at ambient or elevated temperatures.
- the mometasone furoate, dissolved in a portion of the hexylene glycol/water mixture is added to the oil phase.
- the ingredients are thoroughly mixed so that the product is homogeneous.
- Processing equipment suitable for preparing the cream are known in the art and include colloid mills, homogenizers, roller mills, propeller mixers and the like.
- An anti-inflammatory cream is prepared from the following ingredients:
- An anti-inflammatory cream is prepared from the following ingredients:
- An anti-inflammatory cream is prepared from the following ingredients:
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Semiconductor Memories (AREA)
- Insulated Gate Type Field-Effect Transistor (AREA)
Priority Applications (24)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/914,227 US4808610A (en) | 1986-10-02 | 1986-10-02 | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| ZA877401A ZA877401B (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| CA000548400A CA1294877C (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| JP62506126A JPH0643317B2 (ja) | 1986-10-02 | 1987-10-01 | 抗炎症クリーム組成物 |
| PCT/US1987/002470 WO1988002257A1 (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| AT87114368T ATE62815T1 (de) | 1986-10-02 | 1987-10-01 | Entzuendungshemmende creme. |
| IL84055A IL84055A (en) | 1986-10-02 | 1987-10-01 | Topical anti-inflammatory cream composition containing mometasone furoate |
| EP87114368A EP0262681B1 (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| ES198787114368T ES2038643T3 (es) | 1986-10-02 | 1987-10-01 | Procedimiento para la obtencion de una composicion farmaceutica topica. |
| DE8787114368T DE3769568D1 (de) | 1986-10-02 | 1987-10-01 | Entzuendungshemmende creme. |
| AU80712/87A AU603837B2 (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| KR1019880700606A KR930010585B1 (ko) | 1986-10-02 | 1987-10-01 | 소염제 크림 조성물 |
| PH35872A PH23440A (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| IE263387A IE60492B1 (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| EP87906722A EP0318522A1 (en) | 1986-10-02 | 1987-10-01 | Anti-inflammatory cream composition |
| NZ222020A NZ222020A (en) | 1986-10-02 | 1987-10-01 | Substituted pregnadiene-containing anti-inflammatory cream compositions |
| KR1019880700606A KR880701555A (ko) | 1986-10-02 | 1988-05-30 | 소염제 크림 조성물 |
| DK198802950A DK174790B1 (da) | 1986-10-02 | 1988-05-31 | Anti-inflammatorisk cremekomposition |
| NO882417A NO175350C (no) | 1986-10-02 | 1988-06-01 | Fremgangsmåte for fremstilling av et topisk krempreparat for behandling av betennelse |
| OA59548A OA09034A (en) | 1986-10-02 | 1989-03-30 | Anti-inflammatory cream composition |
| FI891552A FI100047B (fi) | 1986-10-02 | 1989-03-31 | Menetelmä stabiilin tooppisen farmaseuttisen seoksen valmistamiseksi |
| GR91400764T GR3002086T3 (en) | 1986-10-02 | 1991-06-07 | Anti-inflammatory cream composition |
| MX9203395A MX9203395A (es) | 1986-10-02 | 1992-06-25 | Composicion de crema antiinflamatoria de furoato de mometasona usando hexilenglicol. |
| HK1025/93A HK102593A (en) | 1986-10-02 | 1993-09-30 | Anti-inflammatory cream composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/914,227 US4808610A (en) | 1986-10-02 | 1986-10-02 | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4808610A true US4808610A (en) | 1989-02-28 |
Family
ID=25434063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/914,227 Expired - Lifetime US4808610A (en) | 1986-10-02 | 1986-10-02 | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4808610A (xx) |
| EP (2) | EP0318522A1 (xx) |
| JP (1) | JPH0643317B2 (xx) |
| KR (2) | KR930010585B1 (xx) |
| AT (1) | ATE62815T1 (xx) |
| AU (1) | AU603837B2 (xx) |
| CA (1) | CA1294877C (xx) |
| DE (1) | DE3769568D1 (xx) |
| DK (1) | DK174790B1 (xx) |
| ES (1) | ES2038643T3 (xx) |
| FI (1) | FI100047B (xx) |
| GR (1) | GR3002086T3 (xx) |
| HK (1) | HK102593A (xx) |
| IE (1) | IE60492B1 (xx) |
| IL (1) | IL84055A (xx) |
| MX (1) | MX9203395A (xx) |
| NO (1) | NO175350C (xx) |
| NZ (1) | NZ222020A (xx) |
| OA (1) | OA09034A (xx) |
| PH (1) | PH23440A (xx) |
| WO (1) | WO1988002257A1 (xx) |
| ZA (1) | ZA877401B (xx) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057500A (en) * | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
| US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| US7312207B2 (en) | 2003-05-23 | 2007-12-25 | Taro Pharmaceuticals North America, Inc. | Topical steroid cream formulations |
| US20080311058A1 (en) * | 2007-06-18 | 2008-12-18 | Connopco, Inc., D/B/A Unilever | Stable high internal phase emulsions and compositions comprising the same |
| US20090082318A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched mometasone |
| US20100029602A1 (en) * | 2007-04-11 | 2010-02-04 | Perrigo Israel Pharmaceuticals Ltd. | Low-dose mometasone formulations |
| US20100240621A1 (en) * | 2007-09-10 | 2010-09-23 | Glenmark Pharmaceuticals Ltd. | Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid |
| WO2011147536A2 (en) | 2010-05-26 | 2011-12-01 | Almirall, S.A. | Topical pharmaceutical compositions |
| US20110305649A1 (en) * | 2010-06-14 | 2011-12-15 | Conopco, Inc., D/B/A Unilever | High Humectant High Internal Phase Emulsion |
| US8398959B2 (en) | 2010-12-06 | 2013-03-19 | Conopco, Inc. | Compositions and methods for imparting a sunless tan with functionalized adjuvants |
| US8728497B2 (en) | 2009-05-12 | 2014-05-20 | Galenica Ab | Oil-in-water emulsion of mometasone and propylene glycol |
| US8821839B2 (en) | 2010-10-22 | 2014-09-02 | Conopco, Inc. | Compositions and methods for imparting a sunless tan with a vicinal diamine |
| US8961942B2 (en) | 2011-12-13 | 2015-02-24 | Conopco, Inc. | Sunless tanning compositions with adjuvants comprising sulfur comprising moieties |
| RU2548764C2 (ru) * | 2013-01-25 | 2015-04-20 | Открытое Акционерное Общество "Татхимфармпрепараты" | Лекарственное средство для лечения дерматозов (варианты) |
| US20160243025A1 (en) * | 2013-04-29 | 2016-08-25 | Helene Bertrand | Topical Formulation for Pain Relief |
| WO2022038485A1 (en) * | 2020-08-20 | 2022-02-24 | Pfizer Inc. | Stable topical formulations of 1(r)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol |
| WO2024133039A1 (en) | 2022-12-20 | 2024-06-27 | Galenica Derma Ab | Novel composition for local skin treatment |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE309353T1 (de) * | 1987-09-23 | 1991-02-07 | L'oreal, Paris | Hautbehandlungsmittel als aerosolschaum, das vasiline enthaelt. |
| US5223340A (en) * | 1989-04-20 | 1993-06-29 | Peach State Labs, Inc. | Stain resistant polyamide fibers |
| KR960013445B1 (ko) * | 1990-09-10 | 1996-10-05 | 쉐링 코포레이션 | 모메타손 푸로에이트 모노하이드레이트 및 이의 제조방법 |
| US6127353A (en) * | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| US5407678A (en) * | 1993-09-01 | 1995-04-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Petroleum jelly cream |
| KR100361240B1 (ko) * | 1993-12-21 | 2003-01-29 | 쉐링 코포레이션 | 건선치료용약제학적조성물 |
| US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| WO2000012096A1 (fr) * | 1998-08-26 | 2000-03-09 | Shionogi & Co., Ltd. | Pommades anti-inflammatoires |
| FR2787025B1 (fr) * | 1998-12-14 | 2002-10-11 | Oreal | Composition sous forme d'emulsion h/e a forte teneur en cire et ses utilisations dans les domaines cosmetique et dermatologique |
| US7897976B2 (en) | 2002-02-19 | 2011-03-01 | Hoya Corporation | Light-emitting device of field-effect transistor type |
| DE102006034883A1 (de) * | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
| WO2010048675A1 (en) * | 2008-10-30 | 2010-05-06 | Ego Pharmaceuticals Pty Ltd | Anti-inflammatory pharmaceutical compositions comprising a corticosteroid, hexylene glycol and water |
| JP2015196663A (ja) * | 2014-04-01 | 2015-11-09 | ロレアル | ナノ又はマイクロエマルションの形態の組成物 |
| FR3039399B1 (fr) * | 2015-07-31 | 2018-08-24 | Idl International Drug Licensing | Creme pour l'admnistration de steroides et son procede de preparation |
| JP6982293B2 (ja) * | 2017-07-25 | 2021-12-17 | 株式会社大阪製薬 | 皮膚外用組成物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070462A (en) * | 1976-10-26 | 1978-01-24 | Schering Corporation | Steroid ointment |
| US4124707A (en) * | 1976-12-22 | 1978-11-07 | Schering Corporation | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor |
| US4201778A (en) * | 1977-11-08 | 1980-05-06 | Schering Corporation | 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates |
| US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
| US4472393A (en) * | 1981-02-02 | 1984-09-18 | Schering Corporation | 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4048310A (en) * | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4083974A (en) * | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| JPS59137408A (ja) * | 1983-01-27 | 1984-08-07 | Taisho Pharmaceut Co Ltd | 軟膏 |
| US4489071A (en) * | 1983-12-09 | 1984-12-18 | Schering Corporation | Betamethasone dipropionate cream |
-
1986
- 1986-10-02 US US06/914,227 patent/US4808610A/en not_active Expired - Lifetime
-
1987
- 1987-10-01 EP EP87906722A patent/EP0318522A1/en active Pending
- 1987-10-01 ZA ZA877401A patent/ZA877401B/xx unknown
- 1987-10-01 IL IL84055A patent/IL84055A/xx not_active IP Right Cessation
- 1987-10-01 JP JP62506126A patent/JPH0643317B2/ja not_active Expired - Lifetime
- 1987-10-01 EP EP87114368A patent/EP0262681B1/en not_active Expired - Lifetime
- 1987-10-01 PH PH35872A patent/PH23440A/en unknown
- 1987-10-01 NZ NZ222020A patent/NZ222020A/xx unknown
- 1987-10-01 DE DE8787114368T patent/DE3769568D1/de not_active Expired - Lifetime
- 1987-10-01 ES ES198787114368T patent/ES2038643T3/es not_active Expired - Lifetime
- 1987-10-01 WO PCT/US1987/002470 patent/WO1988002257A1/en active IP Right Grant
- 1987-10-01 AT AT87114368T patent/ATE62815T1/de not_active IP Right Cessation
- 1987-10-01 CA CA000548400A patent/CA1294877C/en not_active Expired - Lifetime
- 1987-10-01 IE IE263387A patent/IE60492B1/en not_active IP Right Cessation
- 1987-10-01 AU AU80712/87A patent/AU603837B2/en not_active Expired
- 1987-10-01 KR KR1019880700606A patent/KR930010585B1/ko active
-
1988
- 1988-05-30 KR KR1019880700606A patent/KR880701555A/ko not_active IP Right Cessation
- 1988-05-31 DK DK198802950A patent/DK174790B1/da not_active IP Right Cessation
- 1988-06-01 NO NO882417A patent/NO175350C/no unknown
-
1989
- 1989-03-30 OA OA59548A patent/OA09034A/xx unknown
- 1989-03-31 FI FI891552A patent/FI100047B/fi not_active IP Right Cessation
-
1991
- 1991-06-07 GR GR91400764T patent/GR3002086T3/el unknown
-
1992
- 1992-06-25 MX MX9203395A patent/MX9203395A/es active IP Right Grant
-
1993
- 1993-09-30 HK HK1025/93A patent/HK102593A/xx not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070462A (en) * | 1976-10-26 | 1978-01-24 | Schering Corporation | Steroid ointment |
| US4124707A (en) * | 1976-12-22 | 1978-11-07 | Schering Corporation | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor |
| US4201778A (en) * | 1977-11-08 | 1980-05-06 | Schering Corporation | 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates |
| US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
| US4472393A (en) * | 1981-02-02 | 1984-09-18 | Schering Corporation | 3,20-Dioxo-1,4-pregnadiene-17α-ol 17-aromatic heterocycle carboxylates |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057500A (en) * | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
| US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| US7312207B2 (en) | 2003-05-23 | 2007-12-25 | Taro Pharmaceuticals North America, Inc. | Topical steroid cream formulations |
| US20100029602A1 (en) * | 2007-04-11 | 2010-02-04 | Perrigo Israel Pharmaceuticals Ltd. | Low-dose mometasone formulations |
| US20080311058A1 (en) * | 2007-06-18 | 2008-12-18 | Connopco, Inc., D/B/A Unilever | Stable high internal phase emulsions and compositions comprising the same |
| US20100240621A1 (en) * | 2007-09-10 | 2010-09-23 | Glenmark Pharmaceuticals Ltd. | Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid |
| US20090082318A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched mometasone |
| US8728497B2 (en) | 2009-05-12 | 2014-05-20 | Galenica Ab | Oil-in-water emulsion of mometasone and propylene glycol |
| RU2526911C2 (ru) * | 2009-05-12 | 2014-08-27 | Галеника Аб | Эмульсия "масло-в-воде" мометазона и пропиленгликоля |
| US11395827B2 (en) | 2009-05-12 | 2022-07-26 | Galenica Ab | Oil-in-water emulsion of mometasone and propylene glycol |
| EP2962688A1 (en) | 2009-05-12 | 2016-01-06 | Galenica AB | Oil-in-water emulsion of mometasone and propylene glycol |
| US9907807B2 (en) | 2010-05-26 | 2018-03-06 | Almirall, S.A. | Topical pharmaceutical compositions |
| EP2394653A1 (en) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
| WO2011147536A3 (en) * | 2010-05-26 | 2012-06-07 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
| WO2011147536A2 (en) | 2010-05-26 | 2011-12-01 | Almirall, S.A. | Topical pharmaceutical compositions |
| US20110305649A1 (en) * | 2010-06-14 | 2011-12-15 | Conopco, Inc., D/B/A Unilever | High Humectant High Internal Phase Emulsion |
| US8821839B2 (en) | 2010-10-22 | 2014-09-02 | Conopco, Inc. | Compositions and methods for imparting a sunless tan with a vicinal diamine |
| US8398959B2 (en) | 2010-12-06 | 2013-03-19 | Conopco, Inc. | Compositions and methods for imparting a sunless tan with functionalized adjuvants |
| US8961942B2 (en) | 2011-12-13 | 2015-02-24 | Conopco, Inc. | Sunless tanning compositions with adjuvants comprising sulfur comprising moieties |
| RU2548764C2 (ru) * | 2013-01-25 | 2015-04-20 | Открытое Акционерное Общество "Татхимфармпрепараты" | Лекарственное средство для лечения дерматозов (варианты) |
| US20160243025A1 (en) * | 2013-04-29 | 2016-08-25 | Helene Bertrand | Topical Formulation for Pain Relief |
| US9744122B2 (en) * | 2013-04-29 | 2017-08-29 | Helene Bertrand | Topical formulation for pain relief |
| WO2022038485A1 (en) * | 2020-08-20 | 2022-02-24 | Pfizer Inc. | Stable topical formulations of 1(r)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol |
| CN115916260A (zh) * | 2020-08-20 | 2023-04-04 | 辉瑞公司 | 1(r)-4-(5-(4-甲氧基-3-丙氧基苯基)吡啶-3-基)-1,2-氧杂硼杂环戊烷-2-醇的稳定局部制剂 |
| WO2024133039A1 (en) | 2022-12-20 | 2024-06-27 | Galenica Derma Ab | Novel composition for local skin treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02500976A (ja) | 1990-04-05 |
| MX9203395A (es) | 1992-07-01 |
| EP0262681A1 (en) | 1988-04-06 |
| PH23440A (en) | 1989-08-07 |
| JPH0643317B2 (ja) | 1994-06-08 |
| OA09034A (en) | 1991-03-31 |
| HK102593A (en) | 1993-10-08 |
| EP0318522A1 (en) | 1989-06-07 |
| AU603837B2 (en) | 1990-11-29 |
| KR880701555A (ko) | 1988-11-03 |
| DK295088A (da) | 1988-05-31 |
| NO175350B (no) | 1994-06-27 |
| NO882417D0 (no) | 1988-06-01 |
| ZA877401B (en) | 1988-05-25 |
| GR3002086T3 (en) | 1992-12-30 |
| IL84055A (en) | 1991-09-16 |
| FI100047B (fi) | 1997-09-15 |
| AU8071287A (en) | 1988-04-21 |
| DE3769568D1 (de) | 1991-05-29 |
| ES2038643T3 (es) | 1993-08-01 |
| NO175350C (no) | 1994-10-05 |
| FI891552A (fi) | 1989-03-31 |
| WO1988002257A1 (en) | 1988-04-07 |
| IE60492B1 (en) | 1994-07-27 |
| ATE62815T1 (de) | 1991-05-15 |
| FI891552A0 (fi) | 1989-03-31 |
| IL84055A0 (en) | 1988-03-31 |
| CA1294877C (en) | 1992-01-28 |
| NO882417L (no) | 1988-06-01 |
| NZ222020A (en) | 1990-03-27 |
| DK295088D0 (da) | 1988-05-31 |
| KR930010585B1 (ko) | 1993-10-30 |
| EP0262681B1 (en) | 1991-04-24 |
| DK174790B1 (da) | 2003-11-17 |
| IE872633L (en) | 1988-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4808610A (en) | Mometasone furoate anti-inflammatory cream composition using hexylene glycol | |
| US5422361A (en) | Stable cream and lotion bases for lipophilic drug compositions | |
| US5696105A (en) | Antifungal nail composition | |
| KR100381701B1 (ko) | 국소용케토코나졸유제 | |
| EP0410348A1 (en) | Topical spironolactone composition | |
| US4489071A (en) | Betamethasone dipropionate cream | |
| JPH07188027A (ja) | 安定な酪酸ヒドロコルチゾン含有クリーム剤 | |
| JP2557557B2 (ja) | ピロキシカム含有局所投与用医薬組成物 | |
| US4299828A (en) | Corticosteroid stick formulations | |
| US5036050A (en) | Compositions containing thymopentin for topical treatment of skin disorders | |
| US7312207B2 (en) | Topical steroid cream formulations | |
| CA1155394A (en) | Corticosteroid stick formulations | |
| HU207939B (en) | Process for producing podofillotoxin composition containing triglicereides | |
| JPH04159227A (ja) | 消炎鎮痛クリーム剤組成物 | |
| JPS6033366B2 (ja) | 安定化されたトルナフテ−ト含有乳剤 | |
| HU198391B (en) | Process for producing pharmaceutical composition for treating psoriasis | |
| CA2156396A1 (en) | Stable dermatologic preparation containing mycophenolic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SCHERING CORPORATION, GALLOPING HILL ROAD, KENILWO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:MUNAYYER, FARAH J.;SEQUEIRA, JOEL A.;REEL/FRAME:004635/0139 Effective date: 19860924 Owner name: SCHERING CORPORATION, A CORP. OF NEW JERSEY, NEW J Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNAYYER, FARAH J.;SEQUEIRA, JOEL A.;REEL/FRAME:004635/0139 Effective date: 19860924 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |